StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on LENZ Therapeutics Inc (LENZ)

Tue, 07 Jul 2026 07:04:11 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $38.00 price target on LENZ Therapeutics Inc (NASDAQ: LENZ).

The analyst commented: "To facilitate the current VIZZ launch trajectory as a novel topical ophthalmic alternative to reading glasses, the company has implemented a new telehealth prescribing option to accelerate patient access for appropriate prescriptions. With the VIZZ launch having just recently initiated in October 2025, we continue to believe the trajectory will play out over several quarters as prescribers and patients build progressive awareness and engagement with the product. We note the purpose of the new telehealth platform is to add

Form 8-K LENZ Therapeutics, Inc. For: Jun 30

Thu, 02 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26729209.html

Form 8-K LENZ Therapeutics, Inc. For: Jun 30

Thu, 02 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26729209.html

Form SCHEDULE 13G LENZ Therapeutics, Inc. Filed by: MILLENNIUM MANAGEMENT LLC

Fri, 26 Jun 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260626/26699648.html

Form SCHEDULE 13G LENZ Therapeutics, Inc. Filed by: MILLENNIUM MANAGEMENT LLC

Fri, 26 Jun 2026 16:54:00 -0400

si-local-file:///var/storage/secattach/20260626/26699648.html

LENZ Therapeutics licenses VIZZ eye drop to Arrotex for Australia, NZ

Wed, 24 Jun 2026 08:32:01 -0400

LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Arrotex Pharmaceuticals Pty Ltd. have entered into an exclusive license and commercialization agreement for VIZZ (aceclidine ophthalmic solution) 1.44% in Australia and New Zealand, according to a press release issued June 24, 2026.

Under the agreement, LENZ will receive an upfront payment and a profit share of gross margin from product sales. Arrotex will hold exclusive rights to register and commercialize VIZZ for the treatment of presbyopia in both countries. Specific financial terms were not disclosed.

VIZZ received U.S. Food and Drug Administration approval in July 2025 and has been commercially available in the United States

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

Wed, 24 Jun 2026 08:30:00 -0400

Exclusive license and commercialization agreement includes a significant profit share of gross margin from product sales in addition to an upfront license payment to LENZ

SAN DIEGO and MELBOURNE, Australia, June 24, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Arrotex Pharmaceuticals Pty Ltd. (“Arrotex”) today announced an exclusive license and commercialization agreement for Arrotex to register and commercialize VIZZ™ for the treatment of presbyopia in Australia and New Zealand. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

Wed, 24 Jun 2026 08:30:00 -0400

Exclusive license and commercialization agreement includes a significant profit share of gross margin from product sales in addition to an upfront license payment to LENZ

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: RA Capital Healthcare Fund LP

Mon, 15 Jun 2026 20:22:00 -0400

si-local-file:///var/storage/secattach/20260615/26649137.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: RA Capital Healthcare Fund LP

Mon, 15 Jun 2026 20:22:00 -0400

si-local-file:///var/storage/secattach/20260615/26649137.html

Form 4 LENZ Therapeutics, Inc. For: Jun 15 Filed by: Scheiner Zachary